With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51149-08-7,3,6-Dichloropyridazine-4-carboxylic acid,as a common compound, the synthetic route is as follows.
A mixture of a portion (10 g) of the material so obtained, concentrated sulphuric acid(10 drops) and anhydrous ethanol (50 ml) was heated to reflux for 24 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phasewas dried over magnesium sulphate and evaporated. The residue was dissolved in phosphorylchloride (70 ml) and the solution was heated to 70C for 2 hours. The resultant mixture wascooled to ambient temperature, poured onto a mixture of ice and water and extracted with ethylacetate. The organic layer was washed with a saturated aqueous sodium bicarbonate soluiton,dried over magnesium sulphate and evaporated. The residue was purified by columnchromatography on silica using a 4:1 mixture of petroleum ether (b.p 40-60C) and ethylacetate as eluent. There was thus obtained ethyl 3,6-dichloropyridazine-4-carboxylate as an oil (5.7 g); NMR Spectrum: (CDC13) 1.45 (t, 3H), 4.49 (q, 2H), 7.87 (s,1H); Mass Spectrum: M+H4 221.
51149-08-7 3,6-Dichloropyridazine-4-carboxylic acid 433804, apyridazine compound, is more and more widely used in various.
Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2004/108707; (2004); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem